Polyclonal Dsg2 antibody and the immunogenic epitope derived from EC2 domain suppress EMT and invasion of human melanoma, breast cancer, and prostate cancer cells, consistent with the observation that Dsg2 exhibits a non-adhesive function for cell migration and morphogenesis [1, 5, 6]. Here, DSG2 is linked to prostate cancer.